Inte:Ligand was founded in Maria Enzersdorf, Lower Austria (Niederösterreich) in 2003.[1] They established the company headquarters on Mariahilferstrasse in Vienna, Austria that same year.
In 2007 Inte:Ligand was the recipient of the NÖ Innovation prize (Innovationpreis) for the development of the simulation software LigandScout.[2][3][4][5] As of 2017 there were more than 1500 literature, book chapters and review articles published related to InteLigand software technology in the areas of virtual screening,[6][7][8] 3D-pharmacophore modeling,[9][10][11][12] hit identification,[13][14][15][16][17][18] medicinal chemistry decision support,[19][20][21] activity profiling,[22] docking, fragment-based compound design,[23] protein-protein-interactions,[24] drug-repurposing[25] and molecular dynamics simulations.[26][27][28]
Other applications include the discovery of new Myeloperoxidase ligands,[29]HIV reverse transcriptase inhibitors,[30] applications in anti-viral bio-activity profiling,[31] the development of models to predict HIV Protease activity,[32]Cytochrome P450 activity prediction
,[33]
and simulation models for the activity on Factor Xa.[34]
^Wolber, Gerhard; Langer, Thierry (2005-01-01). "LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters". Journal of Chemical Information and Modeling. 45 (1): 160–169. doi:10.1021/ci049885e. ISSN1549-9596. PMID15667141.
^Karaboga, Arnaud S.; Planesas, Jesús M.; Petronin, Florent; Teixidó, Jordi; Souchet, Michel; Pérez-Nueno, Violeta I. (2013-05-24). "Highly SpecIfic and Sensitive Pharmacophore Model for Identifying CXCR4 Antagonists. Comparison with Docking and Shape-Matching Virtual Screening Performance". Journal of Chemical Information and Modeling. 53 (5): 1043–1056. doi:10.1021/ci400037y. ISSN1549-9596. PMID23577723.
^Sanders, Marijn P. A.; Barbosa, Arménio J. M.; Zarzycka, Barbara; Nicolaes, Gerry A.F.; Klomp, Jan P.G.; de Vlieg, Jacob; Del Rio, Alberto (2012-06-25). "Comparative Analysis of Pharmacophore Screening Tools". Journal of Chemical Information and Modeling. 52 (6): 1607–1620. doi:10.1021/ci2005274. ISSN1549-9596. PMID22646988.
^DeBonis, Salvatore; Skoufias, Dimitrios A.; Indorato, Rose-Laure; Liger, François; Marquet, Bernard; Laggner, Christian; Joseph, Benoît; Kozielski, Frank (2008-03-01). "Structure–Activity Relationship of S-Trityl-l-Cysteine Analogues as Inhibitors of the Human Mitotic Kinesin Eg5". Journal of Medicinal Chemistry. 51 (5): 1115–1125. doi:10.1021/jm070606z. ISSN0022-2623. PMID18266314.
^Polishchuk, Pavel G.; Samoylenko, Georgiy V.; Khristova, Tetiana M.; Krysko, Olga L.; Kabanova, Tatyana A.; Kabanov, Vladimir M.; Kornylov, Alexander Yu.; Klimchuk, Olga; Langer, Thierry (2015-10-08). "Design, Virtual Screening, and Synthesis of Antagonists of αIIbβ3 as Antiplatelet Agents". Journal of Medicinal Chemistry. 58 (19): 7681–7694. doi:10.1021/acs.jmedchem.5b00865. ISSN0022-2623. PMID26367138.
^Barreca, Maria Letizia; De Luca, Laura; Iraci, Nunzio; Rao, Angela; Ferro, Stefania; Maga, Giovanni; Chimirri, Alba (2007-03-01). "Structure-Based Pharmacophore Identification of New Chemical Scaffolds as Non-Nucleoside Reverse Transcriptase Inhibitors". Journal of Chemical Information and Modeling. 47 (2): 557–562. doi:10.1021/ci600320q. ISSN1549-9596. PMID17274611.
^Langer, Thierry; Bryant, Sharon D (2013-10-01). "Computational methods for drug target profiling and polypharmacology". In Silico Drug Discovery and Design. Future Science Book Series. Future Science Ltd. pp. 178–188. doi:10.4155/ebo.13.417. ISBN978-1-909453-01-2.
^Deyon-Jung, Laurence; Morice, Christophe; Chéry, Florence; Gay, Julie; Langer, Thierry; Frantz, Marie-Céline; Rozot, Roger; Dalko-Csiba, Maria (2016-03-16). "Fragment pharmacophore-based in silico screening: a powerful approach for efficient lead discovery". Med. Chem. Commun. 7 (3): 506–511. doi:10.1039/c5md00444f. ISSN2040-2511.
^Golestanian, Sahand; Sharifi, Amirhossein; Popowicz, Grzegorz M.; Azizian, Homa; Foroumadi, Alireza; Szwagierczak, Aleksandra; Holak, Tad A.; Amanlou, Massoud (2016-01-15). "Discovery of novel dual inhibitors against Mdm2 and Mdmx proteins by in silico approaches and binding assay". Life Sciences. 145: 240–246. doi:10.1016/j.lfs.2015.12.047. PMID26746660.
^Barreca, M. L.; De Luca, L.; Iraci, N.; Rao, A.; Ferro, S.; Maga, G.; Chimirri, A (2007). "Structure-Based Pharmacophore Identification of New Chemical Scaffolds as Non-Nucleoside Reverse Transcriptase Inhibitors". J. Chem. Inf. Model. 47 (2): 557–562. doi:10.1021/ci600320q. PMID17274611.
^Steindl, T. M; Schuster, D.; Wolber, G.; Laggner, C.; Langer, T. (2007). "High-throughput structure-based pharmacophore modelling as a basis for successful parallel virtual screening". J. Comput.-Aided Mol. Des. 20 (12): 703–715. doi:10.1007/s10822-006-9066-y. PMID17009092. S2CID32857983.
^Steindl, T. M; Schuster, Laggner; Chuang, K.; Hoffmann, R.; Langer, T. (2007). "Parallel Screening and Activity Profiling with HIV Protease Inhibitor Pharmacophore Models". J. Chem. Inf. Model. 47 (2): 563–571. doi:10.1021/ci600321m. PMID17381173.
^Schuster, D.; Laggner, C.; Steindl, T. M.; Langer, T. (2006). "Development and validation of an in silico P450 profiler based on pharmacophore models". Curr. Drug Discov. Technol. 3 (1): 1–48. doi:10.2174/157016306776637609. PMID16712462.
^Krovat, E. M.; Fruhwirth, K. H.; Langer, T. (2005). "Pharmacophore Identification, in Silico Screening, and Virtual Library Design for Inhibitors of the Human Factor Xa". J. Chem. Inf. Model. 45 (1): 146–159. doi:10.1021/ci049778k. PMID15667140.